Major Medical Groups Release First Joint Nutrition Guidelines for GLP-1s

Key Takeaways:

• Four major medical organizations released the first joint clinical advisory on nutritional priorities for GLP-1 therapy, published simultaneously across four peer-reviewed journals
• The guidelines emphasize eight key nutritional priorities including adequate protein intake, preventing muscle loss, and managing gastrointestinal side effects
• Research shows proper nutrition support can optimize GLP-1 effectiveness while addressing common challenges like adherence and weight regain
• The advisory addresses real-world problems: about half of people discontinue GLP-1s within a year and regain weight without proper nutritional support

Groundbreaking Collaboration Sets New Standards for GLP-1 Nutrition Care

In an unprecedented move, four leading organizations in lifestyle medicine, obesity medicine, and nutrition—the American College of Lifestyle Medicine (ACLM), the American Society for Nutrition (ASN), the Obesity Medicine Association (OMA), and The Obesity Society (TOS)—have jointly released a clinical advisory titled "Nutritional Priorities to Support GLP-1 Therapy for Obesity." This represents the first collaborative effort of its kind to address the nutritional needs of people taking GLP-1 medications.

Published across four peer-reviewed journals, this consensus-based guidance reflects an interdisciplinary collaboration to help clinicians support patients receiving GLP-1 receptor agonists for obesity care with evidence-based nutritional and behavioral strategies. The advisory addresses a critical gap in clinical practice, where people on these powerful medications often receive limited nutritional guidance despite the importance of diet in optimizing treatment outcomes.

Data shows that about half of people quit within a year, then rapidly regain weight, making proper nutritional support essential for long-term success. People seldom get nutritional guidance from their doctors, and the drugs alone do not make for a quick or lasting fix without also changing eating patterns for the healthier.

Eight Core Nutritional Priorities for GLP-1 Success

The joint advisory outlines specific priorities that healthcare providers should address when prescribing GLP-1 medications. The advisory outlines eight key nutritional priorities to support people on GLP-1 medications, emphasizing the importance of (1) patient-centered initiation of therapy, (2) careful baseline nutritional assessment, (3) management of gastrointestinal side effects, (4) personalized, nutrient-dense, minimally processed diets, (5) prevention of micronutrient deficiencies (6) adequate protein intake and strength training to preserve lean mass, (7) leveraging a good diet to maximize weight reduction, and (8) promoting other lifestyle changes around activity, sleep, mental stress, substance use, and social connections to maximize long-term success.

Protein intake emerges as a particularly critical factor. Pooled data from both groups showed a significant reduction in carbohydrate, protein, and fat intake; the liraglutide group showed a 17.1 % reduction in protein intake, a 22.7 % reduction in fat intake and a 12.2 % reduction in carbohydrate intake compared to baseline. This reduction in protein intake raises concerns about muscle preservation during weight loss, making adequate protein consumption essential for anyone taking semaglutide or similar medications.

In the absence of structured nutrition and exercise efforts, loss of muscle and bone may be exacerbated by intermittent use of GLP-1s and weight regain or "weight cycling," increasing risk of sarcopenic obesity. This highlights why the advisory emphasizes the combination of proper nutrition and strength training.

Addressing Real-World Challenges in GLP-1 Treatment

The guidelines come at a crucial time as GLP-1 medications become more widely used. In 2024, 6% of United States (US) adults report current GLP-1 use, and 12% report current or past use—rising to 22% among individuals told by a clinician that they have overweight or obesity. Despite this growing utilization, significant challenges remain.

These include gastrointestinal (GI) side effects; risk of inadequate nutrient intake from reduced food intake combined with insufficient nutritional counseling; potential loss of significant muscle mass and bone density that can compromise long-term health outcomes. The advisory provides practical strategies to address each of these challenges through targeted nutritional interventions.

Nutrition becomes even more important for people who take GLP-1s, says Suzy Badaracco, a nutritionist, chef and CEO of marketing research firm Culinary Tides. "It's about making every bite count," she explains, emphasizing the importance of nutrient density when appetite is reduced.

The advisory also addresses the broader context of treatment. During GLP-1 use, nutritional and medical management of gastrointestinal side effects is critical, as is navigating altered dietary preferences and intakes, preventing nutrient deficiencies, preserving muscle and bone mass through resistance training and appropriate diet, and complementary lifestyle interventions.

Research Shows Benefits of Integrated Approach

Clinical evidence supports the integrated approach outlined in the advisory. In the STEP 3 trial of semaglutide combined with intensive lifestyle intervention (30 counseling visits across 68 weeks, including nutrition, physical activity, and other behavioral strategies, plus 8 initial weeks of meal replacements with liquid shakes, meal bars, or portion-controlled meals), individuals experienced a 16 % reduction from baseline in body weight (versus 5.7 % with intensive lifestyle intervention alone).

This compares favorably to standard care approaches. In comparison, the STEP 1 trial that included semaglutide with general nutrition and physical activity instructions demonstrated a 14.9 % weight reduction from baseline (versus 2.4 % with general nutrition and physical activity instructions alone). The difference suggests that comprehensive nutritional support can enhance the effectiveness of GLP-1 therapy.

Research also shows that proper nutrition counseling can improve eating behaviors beyond weight loss. An observational study reported that the addition of dietary counseling combined with regular exercise for people on semaglutide was associated with reduced emotional eating (72.5 % vs 11.5 %; p < 0.0001), less external eating (27.5 % vs 10.1 %; p < 0.0001), and fewer binge-eating episodes (47.8 % vs 10.1 %; p < 0.0001).

Global Recognition of Nutritional Importance

The timing of this advisory aligns with growing international recognition of the need for comprehensive GLP-1 care. With the new guideline, WHO issues conditional recommendations for using these therapies to support people living with obesity in overcoming this serious health challenge, as part of a comprehensive approach that includes healthy diets, regular physical activity and support from health professionals.

This global perspective reinforces the advisory's emphasis on treating obesity as a complex condition requiring multifaceted support rather than relying on medication alone. "While medication alone won't solve this global health crisis, GLP-1 therapies can help millions overcome obesity and reduce its associated harms."

What This Means for You

If you're considering or currently taking a GLP-1 medication like semaglutide or tirzepatide, this advisory provides a roadmap for optimizing your treatment. The key takeaway is that these medications work best when combined with structured nutritional support and lifestyle changes.

Look for healthcare providers who understand the importance of comprehensive care rather than prescribing medication alone. Many telehealth GLP-1 providers are beginning to incorporate these evidence-based nutritional guidelines into their programs. When evaluating options, ask about their approach to nutrition counseling, protein recommendations, and strategies for managing side effects.

The advisory's emphasis on personalized care means your nutritional needs may differ based on your baseline health, eating patterns, and treatment goals. Working with providers who understand the full scope of GLP-1 care can help you achieve better outcomes while minimizing risks like muscle loss or nutritional deficiencies.

Consider discussing these eight nutritional priorities with your healthcare provider: proper initiation assessment, managing GI side effects, focusing on nutrient-dense foods, preventing deficiencies, maintaining adequate protein intake, combining diet with exercise, and addressing sleep, stress, and social factors that impact long-term success.